The latest price target for Edwards Lifesciences (NYSE:EW) was reported by B of A Securities on December 16, 2024. The analyst firm set a price target for $90.00 expecting EW to rise to within 12 months (a possible 24.57% upside). 69 analyst firms have reported ratings in the last year.

The latest analyst rating for Edwards Lifesciences (NYSE:EW) was provided by B of A Securities, and Edwards Lifesciences upgraded their buy rating.

The last upgrade for Edwards Lifesciences Corp happened on December 16, 2024 when B of A Securities raised their price target to $90. B of A Securities previously had a neutral for Edwards Lifesciences Corp.

The last downgrade for Edwards Lifesciences Corp happened on September 18, 2024 when Jefferies changed their price target from $85 to $70 for Edwards Lifesciences Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edwards Lifesciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edwards Lifesciences was filed on December 16, 2024 so you should expect the next rating to be made available sometime around December 16, 2025.

While ratings are subjective and will change, the latest Edwards Lifesciences (EW) rating was a upgraded with a price target of $82.00 to $90.00. The current price Edwards Lifesciences (EW) is trading at is $72.25, which is out of the analyst’s predicted range.